Literature DB >> 27793882

Cancer Immunology and Immunotherapy.

Ammar Sukari1, Misako Nagasaka2, Ameer Al-Hadidi3, Lawrence G Lum4.   

Abstract

Hanahan and Weinberg described six distinct biological properties of cancer cells that enable tumor growth and metastasis. These properties were referred to as the traditional hallmarks of cancer. Recent discoveries further elucidated hallmarks including evasion of immune destruction by tumor cells that disrupt anticancer response pathways. This review discusses cancer immunology and new treatment strategies aimed at restoration of antitumor immune responses. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CTLA4; Cancer immunology; PD1; PDL1; checkpoint inhibitor; immunotherapy

Mesh：

Year:  2016        PMID： 27793882     DOI： 10.21873/anticanres.11144

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  30 in total

Review 1.  Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Authors:  Mahmoud Chaker; Audrey Minden; Suzie Chen; Robert H Weiss; Eduardo N Chini; Amit Mahipal; Asfar S Azmi
Journal:  Expert Opin Ther Targets       Date:  2017-12-10       Impact factor: 6.902

Review 2.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 3.  DNA methylation in the tumor microenvironment.

Authors:  Meng-Wen Zhang; Kenji Fujiwara; Xu Che; Shu Zheng; Lei Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2017-05       Impact factor: 3.066

Review 4.  The evolution of interventional oncology in the 21st century.

Authors:  Thomas Helmberger
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.039

5.  YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer.

Authors:  Fangfang Lai; Ming Ji; Lei Huang; Yunchen Wang; Nina Xue; Tingting Du; Kai Dong; Xiaoqing Yao; Jing Jin; Zhiqiang Feng; Xiaoguang Chen
Journal:  Acta Pharm Sin B       Date:  2022-03-04       Impact factor: 14.903

6.  Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.

Authors:  Tatsuo Matsuda; Hiroya Takeuchi; Toshiharu Sakurai; Shuhei Mayanagi; Eisuke Booka; Tomonobu Fujita; Hajime Higuchi; Junichi Taguchi; Yasuo Hamamoto; Hiromasa Takaishi; Hirofumi Kawakubo; Masato Okamoto; Makoto Sunamura; Yutaka Kawakami; Yuko Kitagawa
Journal:  Oncol Lett       Date:  2018-05-17       Impact factor: 2.967

7.  Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.

Authors:  Joanna Roopkumar; Shadi Swaidani; Ann S Kim; Bicky Thapa; Lorenzo Gervaso; Brian P Hobbs; Wei Wei; Tyler J Alban; Pauline Funchain; Suman Kundu; Naseer Sangwan; Patricia Rayman; Paul G Pavicic; C Marcela Diaz-Montero; John Barnard; Keith R McCrae; Alok A Khorana
Journal:  Med (N Y)       Date:  2021-03-12

Review 8.  The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.

Authors:  Marie Strickland; Lynn Quek; Bethan Psaila
Journal:  Br J Haematol       Date:  2021-10-07       Impact factor: 8.615

9.  Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy.

Authors:  Ninh M La-Beck; Alberto A Gabizon
Journal:  Front Immunol       Date:  2017-04-06       Impact factor: 7.561

10.  Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Authors:  Adam Diehl; Mark Yarchoan; Alex Hopkins; Elizabeth Jaffee; Stuart A Grossman
Journal:  Oncotarget       Date:  2017-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.